The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. released its corporate update and financial results for the first quarter ended March 31, 2026.
The announcement provides investors and stakeholders with insights into recent business developments and the company’s financial performance during the opening quarter of the year. Further details are available via the official company report.
Earlier this year, Corbus Pharmaceuticals hit a milestone in its CRB-913 obesity trial by initiating the last patient first visit in the 240-participant CANYON-1 study, which is set for completion in summer 2026 (full story). The company also announced plans to present updated Phase 1/2 results for CRB-701 at the 2026 ASCO annual meeting (more details). Both developments come as Corbus continues to advance its pipeline through the year.